| __timestamp | Biogen Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 5078000000 |
| Thursday, January 1, 2015 | 2113100000 | 4717000000 |
| Friday, January 1, 2016 | 1947900000 | 5096000000 |
| Sunday, January 1, 2017 | 1935500000 | 4986000000 |
| Monday, January 1, 2018 | 2106300000 | 4214000000 |
| Tuesday, January 1, 2019 | 2374700000 | 3806000000 |
| Wednesday, January 1, 2020 | 2504500000 | 3671000000 |
| Friday, January 1, 2021 | 2674300000 | 3528000000 |
| Saturday, January 1, 2022 | 2403600000 | 3445000000 |
| Sunday, January 1, 2023 | 2549700000 | 3498000000 |
| Monday, January 1, 2024 | 2403700000 | 3702000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of major players is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Biogen Inc. from 2014 to 2023. Over this period, Teva's SG&A expenses have seen a significant decline of approximately 31%, from $5.08 billion in 2014 to $3.50 billion in 2023. This reduction reflects Teva's strategic cost-cutting measures amidst challenging market conditions.
Conversely, Biogen's SG&A expenses have shown a more stable trend, with a modest increase of about 14% over the same period, peaking at $2.67 billion in 2021. This stability suggests a consistent investment in marketing and administrative functions, aligning with Biogen's focus on maintaining its market position. These contrasting trends highlight the diverse financial strategies employed by these pharmaceutical giants in response to industry dynamics.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Biogen Inc.
Eli Lilly and Company and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Biogen Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and Teva Pharmaceutical Industries Limited
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs TG Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Veracyte, Inc. Trends and Insights
Teva Pharmaceutical Industries Limited and Geron Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Biogen Inc. and United Therapeutics Corporation
Selling, General, and Administrative Costs: Biogen Inc. vs BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ascendis Pharma A/S
Biogen Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared